Under the agreement, Merck will dedicate two of its U.S. facilities to producing Johnson & Johnson’s vaccine. One will produce doses, and the other will be for filling the vials with the vaccine and packaging them before distribution.
Merck discontinued the development of its two COVID-19 vaccine candidates Jan. 25.
More articles on pharmacy:
How J&J’s COVID-19 vaccine compares to Moderna’s, Pfizer’s
Pharmacy operator to pay Roche $43M to settle fraudulent rebates lawsuit
Florida expands eligibility for COVID-19 vaccines at retail pharmacies, physician offices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
